RESUMEN
Na3V2(PO4)2F3 (NVPF) with a NASICON structure has garnered attention as a cathode material owing to its stable 3D structure, rapid ion diffusion channels, high operating voltage, and impressive cycling stability. Nevertheless, the low intrinsic electronic conductivity of the material leading to a poor rate capability presents a significant challenge for practical application. Herein, we develop a series of Ca-doped NVPF/C cathode materials with various Ca2+ doping levels using a simple sol-gel and carbon thermal reduction approach. X-ray diffraction analysis confirmed that the inclusion of Ca2+ does not alter the crystal structure of the parent material but instead expands the lattice spacing. Density functional theory calculations depict that substituting Ca2+ ions at the V3+ site reduces the band gap, leading to increased electronic conductivity. This substitution also enhanced the structural stability, preventing lattice distortion during the charge/discharge cycles. Furthermore, the presence of the Ca2+ ion introduces two localized states within the band gap, resulting in enhanced electrochemical performance compared to that of Mg-doped NVPF/C. The optimal NVPF-Ca-0.05/C cathode exhibits superior specific capacities of 124 and 86 mAh g-1 at 0.1 and 10 C, respectively. Additionally, the NVPF-Ca-0.05/C demonstrates satisfactory capacity retention of 70% after 1000 charge/discharge cycles at 10 C. These remarkable results can be attributed to the optimized particle size, excellent structural stability, and enhanced ionic and electronic conductivity induced by the Ca doping. Our findings provide valuable insight into the development of cathode material with desirable electrochemical properties.
RESUMEN
Cancer is life-threatening disease and being global health problems. Chemotherapy is one of the most used therapy for cancer since many years ago. Chemotherapy is also toxic for normal cell, not specific to the target cells. Consequently, chemotherapy has various side effects. Monoclonal antibody (MAb) has been developed for specific therapy which only has killing effect in cancer cells, but the survival rate of most MAbs around 20%. Therefore, in clinical practice, MAbs administration should combine with chemotherapeutic agents. For effectiveness of therapy and to minimalize adverse effects, anticancer agent with selective cytotoxic effect on target cells is needed, the immunotoxin. OBJECTIVE: This study introduces a novel approach to conjugate monoclonal antibody (Cetuximab) and toxin (Puromycin), in order to selectively inhibit proliferation of triple negative breast cancer (TNBC) and to enhance the efficacy of MAb in target cells killing. METHODS: Cetuximab was conjugated with Puromycin using a linker, i.e SATP (Succinimidyl-acetylthiopropionate) and tested on triple negative breast cancer cell lines (MDA-MB-231) which expressed EGFR (epidermal growth factor receptor). Cetuximab is MAb which targets EGFR. MCF-7 was used as control cells since it has low or no EGFR expression. Cell counting were conducted as viability assay at 24 hours, 48 hours, and 72 hours after treatment. RESULTS: The results showed significant reduction of live cells number in Conjugate 20 µg/mL cultured in MDA-MB-231 compared to MCF-7 after 24 hours, 48 hours, and 72 hours incubation. In all time period of incubation, significant reduction of MDA-MB-231 live cells number was also observed in Conjugate 20 µg/mL compared to Cetuximab 20 µg/mL. CONCLUSION: Synthesized conjugate showed its target-specific effect in TNBC and improved the efficacy of Cetuximab on TNBC. In the future, this conjugate can be a potential anticancer therapy in treating triple-negative breast cancer.